Literature DB >> 2306063

Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues. A clinicopathologic study of four patients.

J Varga1, J Peltonen, J Uitto, S Jimenez.   

Abstract

We describe the cases of four women who developed a scleroderma-like syndrome during L-tryptophan treatment for insomnia or tinnitus. The illness was characterized by swelling of the extremities, skin rash, myalgia, and elevation of the peripheral blood eosinophil count, followed by rapidly progressive cutaneous and subcutaneous induration. The histopathologic examination of affected skin showed thickening of the fascia, deep dermal fibrosis, and accumulation of mononuclear cells and abundant eosinophils. The expression of the type I procollagen gene was examined by in-situ hybridizations of affected skin with a human sequence-specific complementary DNA (cDNA). Increased hybridization signals were detected in the deep dermis and fascia, indicating enhanced expression of the collagen gene. The temporal association of L-tryptophan use and the development of a scleroderma-like illness in these four patients suggests a causal relation between L-tryptophan or its metabolites and the stimulation of fibroblast collagen gene expression that results in dermal and fascial fibrosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306063     DOI: 10.7326/0003-4819-112-5-344

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

1.  Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome.

Authors:  W F Owen; J Petersen; D M Sheff; R D Folkerth; R J Anderson; J M Corson; A L Sheffer; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  The eosinophilia-myalgia syndrome.

Authors:  S A Jimenez; J Varga
Journal:  West J Med       Date:  1990-09

3.  Transcription factors nuclear factor I and Sp1 interact with the murine collagen alpha 1 (I) promoter.

Authors:  M C Nehls; R A Rippe; L Veloz; D A Brenner
Journal:  Mol Cell Biol       Date:  1991-08       Impact factor: 4.272

4.  Abnormalities of the coronary arteries, neural structures and conduction system of the heart observed postmortem in the eosinophilia-myalgia syndrome, with a discussion of comparative findings from the toxic oil syndrome.

Authors:  T N James
Journal:  Trans Am Clin Climatol Assoc       Date:  1991

Review 5.  Tryptophan. Current status and future trends for oral administration.

Authors:  L D Kaufman; R M Philen
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

6.  Expression of types I, III and IV collagen genes in fibrotic skin and nerve lesions of toxic oil syndrome patients.

Authors:  J J Gomez-Reino; M Sandberg; P E Carreira; E Vuorio
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

7.  Gastrointestinal involvement in L-tryptophan (L-Trp) associated eosinophilia-myalgia syndrome (EMS).

Authors:  K De Schryver-Kecskemeti; K W Bennert; G S Cooper; P Yang
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

8.  A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).

Authors:  R M Silver; A Ludwicka; M Hampton; T Ohba; S A Bingel; T Smith; R A Harley; J Maize; M P Heyes
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

9.  Eosinophilic fasciitis presenting with a reactive hepatitis.

Authors:  A E Loeliger; H R van den Brink; R H Derksen; J W Bijlsma
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

10.  Detection of antineutrophil cytoplasmic antibody in a patient with L-tryptophan induced eosinophilia-myalgia syndrome.

Authors:  A M Cilursu; J Goeken; R R Olson
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.